All-oral triplet combination of ixazomib, lenalidomide, and dexamethasone in newly diagnosed transplant-eligible multiple myeloma patients: final results of the phase II IFM 2013-06 study.
Haematologica
; 107(7): 1693-1697, 2022 07 01.
Article
in En
| MEDLINE
| ID: mdl-35172566
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Multiple Myeloma
Type of study:
Diagnostic_studies
Limits:
Humans
Language:
En
Journal:
Haematologica
Year:
2022
Document type:
Article